238 related articles for article (PubMed ID: 21116779)
1. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
[TBL] [Abstract][Full Text] [Related]
2. Uricase from Bacillus fastidious loaded in alkaline enzymosomes: enhanced biochemical and pharmacological characteristics in hypouricemic rats.
Tan Q; Zhang J; Wang N; Li X; Xiong H; Teng Y; He D; Wu J; Zhao C; Yin H; Zhang L
Eur J Pharm Biopharm; 2012 Sep; 82(1):43-8. PubMed ID: 22705639
[TBL] [Abstract][Full Text] [Related]
3. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
[TBL] [Abstract][Full Text] [Related]
4. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
Sherman MR; Saifer MG; Perez-Ruiz F
Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
[TBL] [Abstract][Full Text] [Related]
5. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
[TBL] [Abstract][Full Text] [Related]
7. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
Zhang C; Fan K; Luo H; Ma X; Liu R; Yang L; Hu C; Chen Z; Min Z; Wei D
Int J Pharm; 2012 Jul; 430(1-2):307-17. PubMed ID: 22503989
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
[TBL] [Abstract][Full Text] [Related]
9. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase.
Abuchowski A; Karp D; Davis FF
J Pharmacol Exp Ther; 1981 Nov; 219(2):352-4. PubMed ID: 7288624
[TBL] [Abstract][Full Text] [Related]
10. Comparison of modification of a bacterial uricase with N-hydroxysuccinimide esters of succinate and carbonate of monomethoxyl poly(ethylene glycol).
Zhang C; Yang X; Gao A; Hu X; Pu J; Liu H; Feng J; Liao J; Li Y; Liao F
Biotechnol Appl Biochem; 2014; 61(6):683-90. PubMed ID: 24512141
[TBL] [Abstract][Full Text] [Related]
11. [The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes].
Deng X; He D; Xiong HR; Zhou YL; Zhang JQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 46(5):688-91. PubMed ID: 26619536
[TBL] [Abstract][Full Text] [Related]
12. Use of the uricase-inhibited rat as an animal model in toxicology.
Stavric B; Nera EA
Clin Toxicol; 1978; 13(1):47-74. PubMed ID: 367691
[TBL] [Abstract][Full Text] [Related]
13. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
[TBL] [Abstract][Full Text] [Related]
14. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
[TBL] [Abstract][Full Text] [Related]
15. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
Kelly SJ; Delnomdedieu M; Oliverio MI; Williams LD; Saifer MGP; Sherman MR; Coffman TM; Johnson GA; Hershfield MS
J Am Soc Nephrol; 2001 May; 12(5):1001-1009. PubMed ID: 11316859
[TBL] [Abstract][Full Text] [Related]
16. Effects of modification of amino groups with poly(ethylene glycol) on a recombinant uricase from Bacillus fastidiosus.
Zhang C; Yang X; Feng J; Yuan Y; Li X; Bu Y; Xie Y; Yuan H; Liao F
Biosci Biotechnol Biochem; 2010; 74(6):1298-301. PubMed ID: 20530883
[TBL] [Abstract][Full Text] [Related]
17. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
Chua CC; Greenberg ML; Viau AT; Nucci M; Brenckman WD; Hershfield MS
Ann Intern Med; 1988 Jul; 109(2):114-7. PubMed ID: 3289428
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man.
Yamada I; Fukunari A; Osajima T; Kamezawa M; Mori H; Iwane J
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1123-5. PubMed ID: 15571214
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of lipid vesicles containing uricase.
Tan QY; Wang N; Yang H; Chen L; Xiong HR; Zhang LK; Liu J; Zhao CJ; Zhang JQ
Drug Deliv; 2010 Jan; 17(1):28-37. PubMed ID: 22747073
[TBL] [Abstract][Full Text] [Related]
20. Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice.
Wang Y; Zhu JX; Kong LD; Yang C; Cheng CH; Zhang X
Basic Clin Pharmacol Toxicol; 2004 May; 94(5):232-7. PubMed ID: 15125693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
